Cabenuva

There is emerging evidence that long-acting injectable therapies, such as rilpivirine and cabotegravir, may offer significant benefits for people with HIV, especially those who struggle with adherence to daily oral medications. These injections, administered every few months, could improve adherence and provide a more convenient alternative to daily pills. The article highlights ongoing challenges, including

Many barriers exist with CAB/RPV implementation that may be easily managed. For successful implementation, intense collaboration among care team members, external support, and excellent communication are necessary. This article discusses the lessons from LA CAB/RPV injections and strategies to improve access and utilization.

Since 2021, the Ward 86 Clinic at the University of California, San Francisco (UCSF) has conducted a pilot study on injected CAB/RPV in patients with viremia. The study enrolled 133 patients who received injected CAB/RPV, 57 of whom had viremia. The mean log10 viral load of these 57 patients was 4.21, and the mean CD4

Intramuscular cabotegravir/rilpivirine (IM CAB/RPV) are metabolized by UGT1A1/CYP3A4. Efavirenz induces both enzymes; therefore, switching from an efavirenz-containing regimen to IM CAB/RPV could possibly result in suboptimal levels. Due to their long dosing interval, clinical studies with IM CAB/RPV are challenging. We used physiologically based pharmacokinetic (PBPK) modeling to simulate switching from efavirenz to IM CAB/RPV.

Despite the availability of safe and effective oral combination antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending the HIV epidemic. Long-acting injectable antiretroviral therapy was developed as an alternative to daily oral therapy. This review summarizes the current literature on the efficacy of long-acting cabotegravir plus rilpivirine for the treatment of

“Treatment with long-acting (LA) ART may improve adherence and health-related quality of life. The objective of this study was to evaluate the cost-effectiveness of cabotegravir + rilpivirine (CAB+RPV) LA administered every 2 months (Q2M) compared with current ART administered as daily oral single-tablet regimens (STRs) from a Spanish National Healthcare System perspective. This study demonstrated

Data support the use of long-acting cabotegravir plus rilpivirine dosed every 2 months as a complete antiretroviral regimen that has similar efficacy to a commonly used integrase strand transfer inhibitor-based first-line regimen while addressing unmet psychosocial issues associated with daily oral treatment.

The HIV treatment approach known as long-acting injectable antiretroviral therapy (LAI ART), which includes a bimonthly injection of cabotegravir/rilpivirine, appears promising. People who are hesitant to start LAI ART or who adhere to it poorly and who are not virally suppressed may gain the most from it. However, the acceptability and viability of LAI ART

A full, long-acting (LA) regimen for maintaining HIV-1 virologic suppression consists of cabotegravir (CAB) and rilpivirine (RPV), administered intramuscularly monthly or every two months. In this report, the authors provide the findings from week 152 of the ATLAS-2M antiretroviral treatment research.